<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_BostonU_Description skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:BostonU/Description</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV style="width:100%; background-color: grey;"><DIV id="table"><UL id="ulist"><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/Attributions" class="dropbtn" id="onecon"><B>ATTRIBUTIONS</B></A><DIV class="dropdown-content"><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions">Team</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#adv">Advisors</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#pi">PIs</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#spon">Sponsors</A><A style="color:#760E18; text-align:center;" href="https://2016.igem.org/Team:BostonU/Attributions#support">Misc Support</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/Medal_Criteria" class="dropbtn" id="twocon"><B>JUDGING</B></A><DIV class="dropdown-content"><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Medal_Criteria">Medal Criteria</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Engagement">Best Education &amp; Public Engagement</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Basic_Part">Best New Basic Part</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Composite_Part">Best New Composite Part</A><A style="color:#507F54; text-align:center;" href="https://2016.igem.org/Team:BostonU/Part_Collection">Best Part Collection</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/HP/Silver" class="dropbtn" id="threecon"><B>HUMAN PRACTICES</B></A><DIV class="dropdown-content"><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/HP/Silver">Intellectual Property Blog</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/HP/Gold">Bioethics Forums</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/HP/Tours">Industry Visits</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/Collaborations">Collaborations</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/Interlab">Interlab Study</A><A style="color:#BD162A; text-align:center;" href="https://2016.igem.org/Team:BostonU/Safety">Safety</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU/Abstract_and_Motivation" class="dropbtn" id="fourcon"><B>PROJECT</B></A><DIV class="dropdown-content"><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Abstract_and_Motivation">Motivation</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Design">Design</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Proof">Proof of Concept</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Parts">Submitted Parts</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Description">Improved Part Characterization</A><A style="color:#0071A7; text-align:center;" href="https://2016.igem.org/Team:BostonU/Notebook">Notebook</A></DIV></LI><LI id="lists" class="dropdown"><A href="https://2016.igem.org/Team:BostonU" class="dropbtn" id="fivecon" style="height:75px;"><B>HOME</B></A></LI><DIV style="width:100%; margin:0 auto;"><CENTER><DIV><DIV style="font-size:300%; padding:75px 50px 3px 50px; text-align:center; color:#0071A7;">Improved Part Characterization</DIV><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">Our team worked to improve the characterization of a <A href="http://parts.igem.org/Part:BBa_I712004" style="color:blue;"> CMV promoter, BBa_I712004</A>, part from the iGEM Registry. This part originated from the Heidelberg 2009 iGEM team as a “constitutive” promoter that could be expressed in HeLa mammalian cells. The cytomegalovirus (CMV) promoter is commonly used for gene expression in mammalian cells.</P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">
As part of our characterization, this part was also directly compared to several of our Gemini library plasmids, more specifically:  <A href="http://parts.igem.org/Part:BBa_K1875014" style="color:blue;">BBa_K1875014</A>, <A href="http://parts.igem.org/Part:BBa_K1875015" style="color:blue;">BBa_K1875015</A>, <A href="http://parts.igem.org/Part:BBa_K1875016" style="color:blue;">BBa_K1875016</A> and <A href="http://parts.igem.org/Part:BBa_K1875018" style="color:blue;">BBa_K1875018</A>. These new parts were co-transfected into HEK293FT cells with a dCas9-VPR expression vector and the corresponding gRNA expression vectors, and then assayed using flow cytometry. We measured fluorescence of the CMV promoter device relative to these devices.</P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;"> 
Parts BBa_K1875014, BBa_K1875015, and BBa_K1875016 correspond to three of our single operator promoters driving GFP.  In addition to these we compared the CMV to three of our Gemini library plasmids with three multimerized operator sites upstream of a minimal promoter driving GFP, one of which was submitted to the iGEM registry under the code BBa_K1875018.  Flow cytometry found that five of the six Gemini parts we compared to the CMV fluoresced anywhere between half as bright to five times as bright as the CMV.</P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">
The experimental procedures used in this assay involved measuring fluorescence using Mean Fluorescence Intensity (M.F.I.). Thus, the absolute values are arbitrary units, and cannot be directly compared to other expression systems unless re-tested in the same context. Our experiment, however, does reveal the relative strength of the CMV promoter device as compared to both of our well-characterized parts.</P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">BBa_I712004 compared to two Gemini operator promoter plasmids containing the same gRNA operator.  The CMV fluoresced twice as bright as the single operator promoter plasmid BBa_K1875016 (denoted by the singular operator site) and about a fourth as bright as the triple operator promoter plasmid (denoted by the triple operator site).</P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">
CMV compared to three Gemini single operator promoters (BBa_K1875014, BBa_K1875015, and BBa_K1875016 respectively).  The CMV expressed GFP at a greater intensity than all of the single operator promoters with the sole exception of the promoter containing the g3 operator.</P><P style="font-size:150%; padding:5px 150px 15px 150px; color:#0071A7;">BBa_I712004 compared to four triple operator promoters.  The CMV fluoresced anywhere between a third to a fifth as brightly as the four triple operator promoters. We submitted the operator promoter containing g13 to the iGEM registry, under the name BBa_K1875018.</P></DIV></CENTER></DIV></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>